The Swiss Federal Institute of Technology (ETH, Zürich) grants CovalX a Worldwide Exclusive License for the patent covering newly discovered cross-linking molecules.
The ETH is a science and technology university located in the city of Zürich, Switzerland and regularly ranked among the top universities in the world. The licensed molecules, object of the agreement, have been developed in the frame of a KTI collaborative program between the group of Professor Renato Zenobi at the Department of Chemistry and Applied Biosciences and CovalX.